Knowing that TGF-Beta was capable of unlocking its receptor while bound by LAP, the UCSF scientists suspected that these ...

The Guilford Foundation (TGF) has announced the start of its year-long 50th anniversary celebration, which will commemorate ...

About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that ...

The Smad2/3 pathway plays a key role in mediating TGF-β1 inhibition of branching morphogenesis and induction of connective tissue growth factor (CTGF) expression in embryonic lungs. Because a ...

With three growth factor technologies working in harmony—EGF, IGF, and TGF—it helps promote collagen, elastin, and hydration, ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Tribeca Global Natural Resources Limited (TGF). However, you won't necessarily see their names ...